P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups
Amira Marouf,Anne-Ségolène Cottereau,Guillemette Fouquet,Salim Kanoun,Patricia Franchi,Romain Ricci,Michel Meignan,David Sibon,Thomas Gastinne,Cécile Borel,Mohammad Hammoud,Guillaume Sicard,Romane Gille,Doriane Cavalieri,Aspasia Stamatoulas Bastard,Lauriane Clement-Filliatre,Julien Lazarovici,Adrien Chauchet,Luc Mathieu Fornecker,Luc Mathieu Fornecker,Sandy Amorin,Mathieu Roquet,Nicole Raus,René-Olivier Casasnovas,Guillaume Cartron,Herve Ghesquieres,Pauline Brice,Olivier Hermine,Olivier Hermine,Didier Bouscary,Marie-Thérèse Rubio,Jerome Tamburini,Jerome Tamburini,Bénédicte Deau Fischer +33 more
TL;DR: The AMAHRELIS retrospective nationwide French study investigated the real-life outcome of patients with R/R HL mostly treated with BV-based salvage therapies and who received post-ASCT BV maintenance and observed a trend to an increased occurrence of neuropathy in patients receiving BV before transplant without impact on early treatment discontinuation.
Journal ArticleDOI
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
Robert T. Chen,Suzanne Allibone,Nancy L. Bartlett,Pauline Brice,Andy I. Chen,Katrina Pose,Lynn Rich,Vijay Bonthapally,Phillip M. Garfin,Michelle A. Fanale +9 more
TL;DR: This is the first report of BV PRO data in R/R HL and sALCL and the majority of patients reported that their energy level, outlook on life, difficulties with daily activities, ability to participate in physical activities, and overall HRQoL improved compared to those before BV treatment.
Journal ArticleDOI
Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma
Guillaume Manson,Pauline Brice,Charles Herbaux,Maria Gomes da Silva,Krimo Bouabdallah,Bénédicte Deau-Fisher,Juliette Bouteloup,Jean Marc Schiano de Collela,Emmanuelle Nicolas-Virelizier,Marie Maerevoet,Herve Ghesquieres,Aspasia Stamatoulas Bastard,Chloe Antier,Florence Poizeau,Laurent Dercle,Roch Houot +15 more
TL;DR: A significant proportion of patients with relapsed/refractory Hodgkin lymphoma experience prolonged remissions after anti-PD1 discontinuation and thus might be cured and re-treatment with anti- PD1 appears to be efficient.